Table 2.
Antenatal and postnatal characteristics of patients who were treated with antimicrobial agents and underwent follow-up amniocentesis after 1 week from initial amniocentesis
| Resolution of intra-amniotic inflammation | |||
|---|---|---|---|
| Confirmed (n=9) | Not confirmed (n=3) | ||
| Delivery ≥ 34 weeks (n=8) | Delivery < 34 weeks (n=1) | Delivery < 34 weeks (n=3) | |
| Nulliparity | 50% (4/8) | 100% (1/1) | 33.3% (1/3) |
| History of preterm delivery | 12.5% (1/8) | 0% (0/1) | 0% (0/3) |
| Initial amniocentesis | |||
| Gestational age at amniocentesis | 23.4 (21.0–26.7) | 23.7 | 21.4 (21.3–27.4) |
| Positive amniotic fluid culture | 0% (0/8) | 0% (0/1) | 33.3% (1/3) |
| Positive amniotic fluid polymerase chain reaction for Ureaplasma spp. | 14.3% (1/7) | 0% (0/1) | 0% (0/3) |
| Amniotic fluid white blood cell count (cells/mm3) | 16 (0–282) | 4 | 24 (1–2556) |
| Amniotic fluid interleukin-6 (ng/mL) | 8.9 (2.8–26.2) | 3.8 | 24.8 (10.6–35.4) |
| Days from initial amniocentesis to resolutiona | 23 (6–30) | 30 | - |
| Number of amniocenteses | 3.5 (3–7) | 3 | 4 (3–5) |
| Duration of new antibiotic regimen use (days) | 27 (7–66) | 31 | 39 (9–43) |
| Cervical dilatation > 3cm (%) | 75% (6/8) | 100% (1/1) | 100% (3/3) |
| Cervical cerclage for cervical insufficiency | 50% (4/8) | 100% (1/1) | 100% (3/3) |
| Gestational age at delivery (weeks) | 37.8 (34.0–41.3)b | 29.9 | 27.4 (27.0–28.7)b |
| Days from initial amniocentesis to delivery | 101 (66–131)b | 43 | 39 (9–43)b |
| Clinical chorioamnionitis | 0% (0/8) | 0% (0/1) | 0% (0/3) |
| Acute histologic chorioamnionitis | 0% (0/3) | 100% (1/1) | 100% (3/3) |
| Funisitis | 0% (0/3) | 100% (1/1) | 66.7% (2/3) |
| Neonatal mortality | 0% (0/8) | 0% (0/1)- | 0% (0/3) |
| Significant neonatal morbidity | 0% (0/8) | 0% (0/1)- | 66.7% (2/3) |
Data are median (range) or % (n/N).
a
The first amniocentesis without evidence of intra-amniotic infection/inflammation
b
P-value < 0.05